Haemoperfusion with polymyxin B membrane: Recent results for an old debate!

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion.Journal of intensive care · 2025
   Review
2. Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques.Diagnostics (Basel, Switzerland) · 2022
   Review
3. Clinical improvement of sepsis by extracorporeal centrifugal leukocyte apheresis in a porcine model.Journal of translational medicine · 2022
   Article
4. Cytokine removal in human septic shock: Where are we and where are we going?Annals of intensive care · 2019
   Review

Corrections and comments

• Comment on
  Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as